lanreotidi

Lanreotide, sometimes referred to as lanreotidi in some languages, is a long-acting somatostatin analog used in the treatment of acromegaly and certain neuroendocrine tumors. It is a peptide drug that forms a sustained-release depot after deep subcutaneous injection, typically administered every 28 days.

Lanreotide works by binding somatostatin receptors, predominantly sst2 and sst5, on pituitary and neuroendocrine tumor cells. This action suppresses the release of growth hormone and other hormones, leading to lower serum IGF-1 levels. The drug also has anti-secretory and antiproliferative effects that can slow tumor progression in well-differentiated neuroendocrine tumors.

Common indications include the treatment of adults with acromegaly who require medical therapy to control hormone excess, as well as adults with unresectable or metastatic, well-differentiated gastroenteropancreatic neuroendocrine tumors, including pancreatic NETs, where tumor growth control has been sought. In some cases, it is used to help manage symptoms related to hormone excess in certain neuroendocrine tumor syndromes.

Dosing is tailored to the individual and the indication. Typical regimens involve 60 mg every 28 days for acromegaly, with possible escalation to higher doses; for gastroenteropancreatic neuroendocrine tumors, 120 mg every 28 days is commonly used. The Autogel formulation allows for administration by trained clinicians or patients in appropriate settings, with injections given subcutaneously.

Common adverse effects include gastrointestinal symptoms (diarrhea, abdominal pain, nausea), injection-site reactions, and gallbladder changes such as sludge or stones. Less frequent effects may include alterations in glucose tolerance, fatigue, or bradycardia. Patients are monitored with clinical assessment, biomarkers such as IGF-1, imaging, and periodic gallbladder evaluation.

Lanreotide has been marketed under brand names such as Somatuline Depot and Lanreotide Autogel and is produced by Ipsen.